

**Discussions with leaders:** Heinrich Schelbert, a pioneer in assessment of cardiac function and a past *JNM* editor-in-chief, talks with Heiko Schoder and Johannes Czernin about his long career in nuclear medicine. . . . . **Page 1163**

**Effects of <sup>177</sup>Lu dose conversion method:** Brosch-Lenz and members of the SNMMI <sup>177</sup>Lu dosimetry challenge continue their evaluation of sources contributing to variability in dosimetry workflow and calculation of absorbed dose. . . . . **Page 1166**

**Ending the LNT model:** Doss explores factors contributing to the persistence of the linear no-threshold model and offers a suggestion for resolving this contentious and long-standing issue. . . . . **Page 1173**

**Radioembolization of NENs:** Watanabe and colleagues report on the potential of multicompartiment dosimetry in <sup>90</sup>Y glass microsphere radioembolization of neuroendocrine neoplasms, observing higher response rates and longer progression-free survival with higher doses. . . . . **Page 1175**

**Posttreatment PET/CT in HNSCC:** Clement and colleagues evaluate the diagnostic performance of <sup>18</sup>F-FDG PET/CT in detecting subclinical recurrence over a 5-y period after treatment for head and neck squamous cell carcinoma. . . . . **Page 1181**

**<sup>68</sup>Ga-FAPI46 in mesothelioma:** Kessler and colleagues characterize the association of histopathologic FAP expression and <sup>68</sup>Ga-FAPI46 PET uptake in malignant mesothelioma and compare resulting sensitivity, specificity, positive/negative predictive values, and detection rates with those of <sup>18</sup>F-FDG PET/CT and contrast-enhanced CT. . . . . **Page 1188**

**PET/CT and prognosis in anal cancer:** Combet-Curt and colleagues document the predictive value of <sup>18</sup>F-FDG PET/CT in terms of recurrence-free, colostomy-free, and overall survival after radiation therapy of squamous cell carcinoma of the anus, including baseline and posttherapeutic imaging. . . . . **Page 1194**

**PRECISE-MDT study:** Bauckneht and colleagues assess the impact of different imaging modalities on guidance of metastasis-directed therapy and resulting effects on oncologic outcomes within a large, multiinstitutional cohort of patients with oligorecurrent prostate cancer. . . . . **Page 1202**

**PSMA PET with HOXB13 profiling:** Angappalige and colleagues investigate whether SUVs on PSMA PET correlate with expression of Homeobox 13, an oncogenic transcription factor that promotes resistance to androgen receptor-targeted therapies in prostate cancer. . . . . **Page 1210**

**FAP in glioblastoma and gliosarcoma:** Oster and colleagues explore the clinical relevance of FAP expression in gliosarcoma and glioblastoma and the diagnostic and therapeutic implications of the ways in which this expression correlates with <sup>68</sup>Ga-FAP inhibitor-46 PET uptake. . . . . **Page 1217**

**SIRT AD and spatial liver function:** Lu and colleagues identify correlations between <sup>90</sup>Y PET absorbed dose voxel maps and nontumoral changes in regional liver function derived from dynamic MRI before and after selective internal radiation therapy. . . . . **Page 1224**

**VIOLET trial protocol:** Buteau and colleagues report on a planned phase I/II trial to determine whether [<sup>161</sup>Tb]Tb-PSMA-I&T can deliver effective radiation to sites of metastatic prostate cancer with an acceptable safety profile. . . . . **Page 1231**

**[<sup>18</sup>F]-Flotufolastat PET/CT reader agreement:** Kuo and colleagues document inter- and intrareader reproducibility of <sup>18</sup>F-flotufolastat PET/CT scans from 2 phase 3 studies in patients with newly diagnosed and recurrent prostate cancer. . . . . **Page 1239**

**Biomarker for <sup>177</sup>Lu-DOTATATE-induced leukopenia:** Steinhilfer and colleagues identify spleen volume reduction as a reliable and independent predictor of long-term leukopenia risk after peptide receptor radionuclide therapy. . . . . **Page 1244**

**Radiopharmaceuticals targeting NTSR-1:** Fonseca Cabrera and colleagues use multiamine macrocyclic moieties as linkers or chelators in theranostic tracers targeting the neurotensin receptor-1, with a goal of achieving elevated tumor uptake, minimal background interference, and prolonged tumor retention. . . . . **Page 1250**

**FAP-targeted radiopharmaceutical therapy:** Mukkamala and colleagues detail the design, development, and preclinical evaluation of a new FAP-targeted radioligand incorporating optimal features of 3 previous therapies and offering high tumor-to-healthy-tissue ratios. . . . . **Page 1257**

**Metaanalysis of [<sup>177</sup>Lu]Lu-PSMA dosimetry:** Ells and colleagues conduct a systematic review and metaanalysis comparing dosimetry methods for the most frequently used [<sup>177</sup>Lu]Lu-PSMA radiopharmaceutical therapy compounds. . . . . **Page 1264**

**STP [<sup>177</sup>Lu]Lu-PSMA dosimetry:** Resch and colleagues compare different single-time-point approaches in radionuclide therapy dosimetry using multiple-time-point protocols as references and call for greater standardization to facilitate reliable STP dosimetry. . . . . **Page 1272**

**Myocardial somatostatin PET uptake:** Larive and colleagues research factors associated with detection

of myocardial uptake on somatostatin PET scans recorded for oncology indications and differential PET criteria that characterize myocardial uptake in acute myocarditis patients. . . . . **Page 1279**

**[<sup>18</sup>F]MFBG LAFOV PET/CT in neuroblastoma:** Borgwardt and colleagues detail experience with a long-axial-field-of-view PET/CT system and this new tracer in children with neuroblastoma, noting shorter scan times, higher sensitivity, and avoidance of general anesthesia or sedation. . . . . **Page 1286**

**Noninvasive imaging of olfaction:** Adilbay and colleagues describe preclinical and human tissue studies on the use of Tsp1a-IR800<sub>p</sub>, a novel fluorescent probe, as a tool to diagnose loss of smell by selectively targeting Nav1.7 expression in olfactory epithelium. . . . . **Page 1293**

**Bimodal guidance in hepatobiliary surgery:** Rietbergen and colleagues summarize development and preclinical studies with <sup>99m</sup>Tc-*h*HEPATO-Cy5, a bimodal tracer that facilitates both fluorescence guidance and radioguidance in surgical resection of deep hepatic lesions. . . . . **Page 1301**

**“Explainable” radiomics:** Captier and colleagues introduce a model- and modality-agnostic tool that explains predictions of multiregion radiomic models by highlighting the contribution of each individual region. . . . . **Page 1307**

**HMC algorithm for uMI Panorama:** Kang and colleagues validate Neurofocus, a head motion-correction algorithm for the uMI Panorama PET/CT system, using a data-driven, statistics-based approach. . . . . **Page 1313**

**NeuroEXPLORER performance:** Li and colleagues provide the physical characteristics, performance evaluation, and first human images with the NeuroEXPLORER, a dedicated brain PET imager with high spatial resolution, high sensitivity, and a 3D camera for markerless continuous motion tracking. . . . . **Page 1320**

**Off-target effects of enzalutamide:** Bauckneht and colleagues compare brain metabolism in patients with metastatic castration-resistant prostate cancer with and without enzalutamide treatment. . . . . **Page 1327**

**False-positive FAPI PET after therapy:** Ludwig and colleagues offer an illustrative case study in a patient with lingering [<sup>68</sup>Ga]Ga-FAPI uptake in postchemotherapy fibronectin tissue and urge caution in interpretation of posttherapy residual lesions. . . . . **Page 1328**